Carfilzomib (PR-171)

Post Date:
Apr 03,2015
Expiry Date:
Apr 02,2016
Detailed Description:
Cas No. :868540-17-4 Quantity: 50g
Specs:98% purity
Payment Method: T/T, Western Union
Carfilzomib (PR-171) is a proteasome inhibitor with IC50 less than 5 nM.

Carfilzomib (CFZ, marketed under the tradename Kyprolis) is a tetrapeptide epoxyketone and a selective proteasome inhibitor. It is an analog of epoxomicin.

The US FDA approved it for relapsed and refractory multiple myeloma on 20 July 2012.
CAS Registry Number:
868540-17-4
Synonyms:
;Carfilzomib(PR-171);PX-171-007;N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide;(S)-2-((S)-2-(2-(2H-1,4-oxazin-4(3H)-yl) acetamido)-4-phenylbutanamide)-4-methyl-N-((S)-1-((S)-4-methyl-1-((R)-2-methyl oxiran-2-yl)-1-oxopentan-2-ylamino)-1-oxo-3-phenylpropan-2-yl)pentanamide;
Molecular Formula:
C₄₀H₅₇N₅O₇
Molecular Weight:
719.9099
Molecular Structure:

Offter to Sell